KeyCorp Cuts Progyny (NASDAQ:PGNY) Price Target to $28.00

Progyny (NASDAQ:PGNY) had its price objective lowered by KeyCorp from $32.00 to $28.00 in a report published on Monday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Other research analysts have also recently issued research reports about the stock. Barclays began coverage on shares of Progyny in a report on Monday, December 8th. They issued an “overweight” rating and a $29.00 target price for the company. Zacks Research downgraded shares of Progyny from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Citigroup upgraded shares of Progyny to an “outperform” rating in a research report on Tuesday, January 20th. Citizens Jmp raised shares of Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 target price on the stock in a research note on Tuesday, January 20th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Progyny in a report on Monday, December 29th. Eight equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $28.80.

Progyny Stock Up 1.5%

PGNY stock opened at $17.79 on Monday. The company’s 50-day moving average price is $23.40 and its two-hundred day moving average price is $23.00. The firm has a market cap of $1.46 billion, a P/E ratio of 27.37, a P/E/G ratio of 1.19 and a beta of 1.01. Progyny has a 12 month low of $16.75 and a 12 month high of $28.75.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. The company had revenue of $318.40 million during the quarter, compared to analysts’ expectations of $314.26 million. Progyny had a return on equity of 11.37% and a net margin of 4.54%.Progyny’s revenue was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.42 EPS. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Equities analysts predict that Progyny will post 0.6 EPS for the current year.

Insider Buying and Selling

In other Progyny news, EVP Allison Swartz sold 4,657 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80. Following the completion of the transaction, the executive vice president owned 89,879 shares in the company, valued at approximately $1,563,894.60. This trade represents a 4.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 9.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Progyny

A number of hedge funds have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd acquired a new position in Progyny in the fourth quarter valued at $25,000. Cetera Trust Company N.A lifted its stake in shares of Progyny by 303.1% in the 2nd quarter. Cetera Trust Company N.A now owns 1,310 shares of the company’s stock valued at $29,000 after purchasing an additional 985 shares during the period. Federated Hermes Inc. boosted its position in shares of Progyny by 147.3% during the 3rd quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock valued at $30,000 after purchasing an additional 819 shares in the last quarter. Hantz Financial Services Inc. boosted its position in shares of Progyny by 79.4% during the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock valued at $43,000 after purchasing an additional 742 shares in the last quarter. Finally, Versant Capital Management Inc grew its stake in Progyny by 61.8% during the third quarter. Versant Capital Management Inc now owns 2,340 shares of the company’s stock worth $50,000 after purchasing an additional 894 shares during the period. Institutional investors own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.